While chemotherapy remains a cornerstone of lung cancer treatment, it often weakens the immune system it relies on for ...

Most patients in KEYNOTE-024 with pembrolizumab as first-line therapy were men, more than 90% were current or former smokers, and approximately 20% had squamous lung cancer.

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ...

Nivolumab (Opdivo, Bristol-Myers Squibb Company) is the first immunotherapy to be available for use in the treatment of lung cancer.The drug has just been approved by the US Food and Drug ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Background: Small cell lung cancer (SCLC) is an aggressive malignancy characterized by a rapid doubling time, high metastatic potential, and risk for relapse, prompting urgent treatment.